123.54USD-1.22%Mkt Cap: 305.12B $P/E: 34.801d ago
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxi…
Industry Peers
Drug Manufacturers - General$1.06TUSDP/E 42.3
$618.61BUSDP/E 29.8
$438.31BUSDP/E 121.0
$309.64BUSDP/E 21.3
$277.04BUSDP/E 22.2
$270.65BUSDP/E 22.0
$247.88BUSDP/E 25.8
$216.35BUSDP/E 25.5
$207.68BUSDP/E 11.8
$196.12BUSDP/E 25.3
$161.19BUSDP/E 17.7
$137.76BUSDP/E 18.5
$117.58BUSDP/E 16.1
$99.17BUSDP/E 19.3
$85.40BUSDP/E 13.8
$29.40BUSDP/E 21.4
MRV
Marvell Technology, Inc.$24.46BUSDP/E 9.3
$11.35BUSDP/E 22.7
$10.67BUSDP/E 18.5
$10.61BUSDP/E 18.4
$6.60BUSDP/E 14.6
$3.55BUSDP/E 14.5
$2.92BUSDP/E 17.8
$66.67MUSD
$38.85MUSD
ELXR
Elixxer Ltd.$9.51MUSD
CELG-RI
Bristol-Myers Squibb Company Ce—
—
FLXN
Horizon Flexible Income ETF—P/E 27.0
ROSE
DocMorris AG—
Indicators:|
Key Statistics
Company
Market Cap305.12B $
Enterprise Value352.37B $
Revenue (TTM)65.77B $
Gross Profit48.63B $
Net Income (TTM)18.25B $
Revenue/Share26.42 USD
Last Price123.54 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees73.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS58933Y1055
Valuation
P/E (Trailing)34.80
P/E (Forward)13.00
PEG6.22
EV/EBITDA11.94
EV/Revenue5.36
P/S4.70
P/B6.73
EPS (TTM)3.53
EPS (Forward)9.62
52W Range
76.6687% of range130.29
52W High130.29 USD
52W Low76.66 USD
Profitability
Gross Margin74.80%
Oper. Margin38.60%
EBITDA Margin44.88%
Profit Margin28.08%
ROE34.70%
ROA13.34%
Growth
Revenue Growth4.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF16.47B $
CapEx (TTM)4.11B $
FCF Margin21.36%
FCF Yield4.60%
Net Debt43.41B $
Net Debt/EBITDA1.47
Balance Sheet
Debt/Equity0.94
Current Ratio1.30
Quick Ratio0.70
Book Value/Sh18.58 USD
Cash/Share2.309 USD
Dividends
Fwd Div Rate3.400 USD
Trail. Div Rate3.280 USD
Div. Yield2.70%
5Y Avg Yield3.01%
Payout Ratio93.52%
Ex-Div DateJun 15, 2026
Pay DateJul 8, 2026
Splits
Last Split1048:1000
Split DateJun 3, 2021
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)132.07 USD
Upside (mean)+6.9%
Target Range100.00 USD – 155.00 USD
$100.00+6.9% to mean$155.00
# Analysts27
Ownership
Shares Out.2.47B
Float2.47B
Insiders0.06%
Institutions82.24%
Short Interest
Short Ratio2.8d
Short % Float1.23%
Short % Out.1.23%
Shares Short30.27M
Short (prev mo.)29.06M
Technical
SMA 50117.95 (+4.7%)
SMA 200108.14 (+14.2%)
Beta0.20
S&P 52W Chg20.11%
Avg Vol (30d)9.38M
Avg Vol (10d)10.75M
Technical Indicators
RSI (14)51.9
MACD2.3777
MACD Signal2.4947
MACD Hist.-0.1171
BB Upper133.58 USD
BB Middle122.59 USD
BB Lower111.60 USD
BB Width17.93%
ATR (14)3.292 USD
Vol Ratio (20d)0.76x